David Charles1, Peter E Konrad2, Joseph S Neimat2, Anna L Molinari3, Michael G Tramontana4, Stuart G Finder5, Chandler E Gill6, Mark J Bliton7, Chris Kao2, Fenna T Phibbs3, Peter Hedera3, Ronald M Salomon4, Kevin R Cannard8, Lily Wang9, Yanna Song9, Thomas L Davis3. 1. Department of Neurology, Vanderbilt University Medical Center, USA. Electronic address: david.charles@vanderbilt.edu. 2. Department of Neurosurgery, Vanderbilt University Medical Center, USA. 3. Department of Neurology, Vanderbilt University Medical Center, USA. 4. Department of Psychiatry, Vanderbilt University Medical Center, USA. 5. Center for Healthcare Ethics, Cedars-Sinai Medical Center, USA. 6. Stritch School of Medicine, Loyola University Chicago, USA. 7. Kaiser Permanente Los Angeles Medical Center, USA. 8. Walter Reed National Military Medical Center, USA. 9. Department of Biostatistics, Vanderbilt University Medical Center, USA.
Abstract
BACKGROUND:Deep brain stimulation (DBS) is an effective and approved therapy for advanced Parkinson's disease (PD), and a recent study suggests efficacy in mid-stage disease. This manuscript reports the results of a pilot trial investigating preliminary safety and tolerability of DBS in early PD. METHODS:Thirty subjects with idiopathic PD (Hoehn & Yahr Stage II off medication), age 50-75, on medication ≥6 months but ≤4 years, and without motor fluctuations or dyskinesias were randomized to optimal drug therapy (ODT) (n = 15) or DBS + ODT (n = 15). Co-primary endpoints were the time to reach a 4-point worsening from baseline in the UPDRS-III off therapy and the change in levodopa equivalent daily dose from baseline to 24 months. RESULTS: As hypothesized, the mean UPDRS total and part III scores were not significantly different on or off therapy at 24 months. Medication requirements in the DBS + ODT group were lower at all time points with a maximal difference at 18 months. With a few exceptions, differences in neuropsychological functioning were not significant. Two subjects in the DBS + ODT group suffered serious adverse events; remaining adverse events were mild or transient. CONCLUSIONS: This study demonstrates that subjects with early stage PD will enroll in and complete trials testing invasive therapies and provides preliminary evidence that DBS is well tolerated in early PD. The results of this trial provide the data necessary to design a large, phase III, double-blind, multicenter trial investigating the safety and efficacy of DBS in early PD.
RCT Entities:
BACKGROUND: Deep brain stimulation (DBS) is an effective and approved therapy for advanced Parkinson's disease (PD), and a recent study suggests efficacy in mid-stage disease. This manuscript reports the results of a pilot trial investigating preliminary safety and tolerability of DBS in early PD. METHODS: Thirty subjects with idiopathic PD (Hoehn & Yahr Stage II off medication), age 50-75, on medication ≥6 months but ≤4 years, and without motor fluctuations or dyskinesias were randomized to optimal drug therapy (ODT) (n = 15) or DBS + ODT (n = 15). Co-primary endpoints were the time to reach a 4-point worsening from baseline in the UPDRS-III off therapy and the change in levodopa equivalent daily dose from baseline to 24 months. RESULTS: As hypothesized, the mean UPDRS total and part III scores were not significantly different on or off therapy at 24 months. Medication requirements in the DBS + ODT group were lower at all time points with a maximal difference at 18 months. With a few exceptions, differences in neuropsychological functioning were not significant. Two subjects in the DBS + ODT group suffered serious adverse events; remaining adverse events were mild or transient. CONCLUSIONS: This study demonstrates that subjects with early stage PD will enroll in and complete trials testing invasive therapies and provides preliminary evidence that DBS is well tolerated in early PD. The results of this trial provide the data necessary to design a large, phase III, double-blind, multicenter trial investigating the safety and efficacy of DBS in early PD.
Authors: Günther Deuschl; Carmen Schade-Brittinger; Paul Krack; Jens Volkmann; Helmut Schäfer; Kai Bötzel; Christine Daniels; Angela Deutschländer; Ulrich Dillmann; Wilhelm Eisner; Doreen Gruber; Wolfgang Hamel; Jan Herzog; Rüdiger Hilker; Stephan Klebe; Manja Kloss; Jan Koy; Martin Krause; Andreas Kupsch; Delia Lorenz; Stefan Lorenzl; H Maximilian Mehdorn; Jean Richard Moringlane; Wolfgang Oertel; Marcus O Pinsker; Heinz Reichmann; Alexander Reuss; Gerd-Helge Schneider; Alfons Schnitzler; Ulrich Steude; Volker Sturm; Lars Timmermann; Volker Tronnier; Thomas Trottenberg; Lars Wojtecki; Elisabeth Wolf; Werner Poewe; Jürgen Voges Journal: N Engl J Med Date: 2006-08-31 Impact factor: 91.245
Authors: Galit Kleiner-Fisman; Jan Herzog; David N Fisman; Filippo Tamma; Kelly E Lyons; Rajesh Pahwa; Anthony E Lang; Günther Deuschl Journal: Mov Disord Date: 2006-06 Impact factor: 10.338
Authors: P D Charles; R M Dolhun; C E Gill; T L Davis; M J Bliton; M G Tramontana; R M Salomon; L Wang; P Hedera; F T Phibbs; J S Neimat; P E Konrad Journal: Parkinsonism Relat Disord Date: 2011-11-21 Impact factor: 4.891
Authors: Michael S Remple; Courtney H Bradenham; C Chris Kao; P David Charles; Joseph S Neimat; Peter E Konrad Journal: Mov Disord Date: 2011-05-03 Impact factor: 10.338
Authors: W M M Schuepbach; J Rau; K Knudsen; J Volkmann; P Krack; L Timmermann; T D Hälbig; H Hesekamp; S M Navarro; N Meier; D Falk; M Mehdorn; S Paschen; M Maarouf; M T Barbe; G R Fink; A Kupsch; D Gruber; G-H Schneider; E Seigneuret; A Kistner; P Chaynes; F Ory-Magne; C Brefel Courbon; J Vesper; A Schnitzler; L Wojtecki; J-L Houeto; B Bataille; D Maltête; P Damier; S Raoul; F Sixel-Doering; D Hellwig; A Gharabaghi; R Krüger; M O Pinsker; F Amtage; J-M Régis; T Witjas; S Thobois; P Mertens; M Kloss; A Hartmann; W H Oertel; B Post; H Speelman; Y Agid; C Schade-Brittinger; G Deuschl Journal: N Engl J Med Date: 2013-02-14 Impact factor: 91.245
Authors: David Charles; Christopher Tolleson; Thomas L Davis; Chandler E Gill; Anna L Molinari; Mark J Bliton; Michael G Tramontana; Ronald M Salomon; Chris Kao; Lily Wang; Peter Hedera; Fenna T Phibbs; Joseph S Neimat; Peter E Konrad Journal: J Parkinsons Dis Date: 2012 Impact factor: 5.568
Authors: Ali Falaki; Hang Jin Jo; Mechelle M Lewis; Barbara O'Connell; Sol De Jesus; James McInerney; Xuemei Huang; Mark L Latash Journal: Clin Neurophysiol Date: 2018-03-09 Impact factor: 3.708
Authors: Melissa Deanna Shepard; Kate Perepezko; Martijn P G Broen; Jared Thomas Hinkle; Ankur Butala; Kelly A Mills; Julie Nanavati; Nicole Mercado Fischer; Paul Nestadt; Gregory Pontone Journal: J Neurol Neurosurg Psychiatry Date: 2019-01-19 Impact factor: 10.154
Authors: Caryl E Sortwell; Mallory L Hacker; David Luke Fischer; Peter E Konrad; Thomas L Davis; Joseph S Neimat; Lily Wang; Yanna Song; Zach R Mattingly; Allyson Cole-Strauss; Jack W Lipton; P David Charles Journal: Neuromodulation Date: 2022-06-14
Authors: Mallory L Hacker; Mahlon R DeLong; Maxim Turchan; Lauren E Heusinkveld; Jill L Ostrem; Anna L Molinari; Amanda D Currie; Peter E Konrad; Thomas L Davis; Fenna T Phibbs; Peter Hedera; Kevin R Cannard; Lea T Drye; Alice L Sternberg; David M Shade; James Tonascia; David Charles Journal: Neurology Date: 2018-06-29 Impact factor: 11.800